Key result
Administration of two 35 unit/kg doses of prothrombin complex concentrate in an adult patient anticoagulated with apixaban resulted in suspected pulmonary embolism.
Case Report (n=1)
Repeat dosing of prothrombin complex concentrate for DOAC-induced bleeding may carry a risk of thrombotic events such as pulmonary embolism and should be used with caution.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for thrombotic risk with repeat PCC dosing in apixaban reversal; larger studies needed before practice implications.
WHAT IS KNOWN AND OBJECTIVE: Prothrombin complex concentrate (PCC) is a plasma-derived concentrate used to replenish clotting factors. There are limited recommendations for treating coagulopathy induced by direct oral anticoagulants (DOAC). Data are limited regarding both total dose and repeated dosing with this population. CASE SUMMARY: We describe a case of an adult patient anticoagulated with apixaban who received two 35 unit/kg doses of PCC resulting in suspected pulmonary embolism. WHAT IS NEW AND CONCLUSION: Treatment of DOAC-induced bleeding remains an "off-label" indication for PCC. Additional doses should be given with caution if given at all and patients monitored closely.
No takes yet. Share an insight, caveat, or question.
King et al. (2018) conducted a case report in Anticoagulated with apixaban (n=1). Prothrombin complex concentrate (PCC) was evaluated on Suspected pulmonary embolism. Administration of two 35 unit/kg doses of prothrombin complex concentrate in an adult patient anticoagulated with apixaban resulted in suspected pulmonary embolism.
Synapse has enriched 10 related papers. Consider them for comparative context: